id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
7351000_2 | Acute non-lymphocytic leukemia occurred in eight women following long-term treatment with Treosulfan (= dihydroxybusulfan) for ovarian carcinoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[31]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Acute non-lymphocytic leukemia\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"eight women\"]], \"start\": [[43]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"eight\"]], \"start\": [[43]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"women\"]], \"start\": [[49]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"Treosulfan (= dihydroxybusulfan)\"]], \"start\": [[90]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Treosulfan\"], [\"dihydroxybusulfan\"]], \"start\": [[90], [104]], \"entity_id\": [\"T11\", \"T12\"]}, \"Disorder\": {\"text\": [[\"ovarian carcinoma\"]], \"start\": [[127]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
9796135_2 | Elderly patients for whom nitrate has been prescribed should be warned of the occurrence of hypotension, leading to unconsciousness. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurrence\"]], \"start\": [[78]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"Elderly patients\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"Elderly\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"nitrate\"]], \"start\": [[26]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"nitrate\"]], \"start\": [[26]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"hypotension\", \"unconsciousness\"]], \"start\": [[92, 116]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
2937155_1 | A patient receiving vancomycin for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"had\"]], \"start\": [[70]], \"entity_id\": [\"T17\"]}, \"Treatment\": {\"text\": [[\"vancomycin\"]], \"start\": [[20]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"vancomycin\"]], \"start\": [[20]], \"entity_id\": [\"T18\"]}, \"Disorder\": {\"text\": [[\"serious staphylococcal infection\"]], \"start\": [[37]], \"entity_id\": [\"T19\"]}}, \"Effect\": {\"text\": [[\"a lupus-like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips\"]], \"start\": [[74]], \"entity_id\": [\"T16\"]}, \"Severity\": {\"text\": [[\"serious\"]], \"start\": [[37]], \"entity_id\": [\"T20\"], \"value\": \"High\"}}"
}
]
}
] |
7436161_2 | Seven patients with hematologic malignancies who were treated with miconazole for either suspected or proven fungal infections developed eight episodes of major adverse cardiorespiratory and anaphylactic reactions. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[127]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"Seven patients with hematologic malignancies\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"Population\": {\"text\": [[\"Seven\"]], \"start\": [[0]], \"entity_id\": [\"T14\"]}, \"Disorder\": {\"text\": [[\"hematologic malignancies\"]], \"start\": [[20]], \"entity_id\": [\"T15\"]}}, \"Treatment\": {\"text\": [[\"miconazole\"]], \"start\": [[67]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"miconazole\"]], \"start\": [[67]], \"entity_id\": [\"T17\"]}, \"Disorder\": {\"text\": [[\"fungal infections\"]], \"start\": [[109]], \"entity_id\": [\"T18\"]}}, \"Effect\": {\"text\": [[\"eight episodes of major adverse cardiorespiratory and anaphylactic reactions\"]], \"start\": [[137]], \"entity_id\": [\"T13\"]}}"
}
]
}
] |
12802933_3 | We report the first case, to our knowledge, of rituximab-related autoimmune hemolytic anemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[57]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"rituximab\"]], \"start\": [[47]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"rituximab\"]], \"start\": [[47]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"autoimmune hemolytic anemia\"]], \"start\": [[65]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"first\"]], \"start\": [[14]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
7606071_1 | Anaphylactoid reactions with intraperitoneal cisplatin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[24]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"intraperitoneal cisplatin\"]], \"start\": [[29]], \"entity_id\": [\"T3\"], \"Route\": {\"text\": [[\"intraperitoneal\"]], \"start\": [[29]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"cisplatin\"]], \"start\": [[45]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Anaphylactoid reactions\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
20185472_2 | Tremor: a newly described adverse event with long-term itraconazole therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[40]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"long-term itraconazole therapy\"]], \"start\": [[45]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"itraconazole\"]], \"start\": [[55]], \"entity_id\": [\"T6\"]}, \"Duration\": {\"text\": [[\"long-term\"]], \"start\": [[45]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Tremor\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
15735923_1 | Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[43]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"myelodysplastic syndrome\"]], \"start\": [[18]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"temozolomide\"]], \"start\": [[49]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"temozolomide\"]], \"start\": [[49]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"recurrent high-grade glioma\"]], \"start\": [[66]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
9366852_3 | It occasionally accompanies the heparin-associated thrombocytopenia and thrombosis syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[40]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"heparin\"]], \"start\": [[32]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"heparin\"]], \"start\": [[32]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"thrombocytopenia and thrombosis syndrome\"]], \"start\": [[51]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
16035204_1 | We report an unusual case of massive fluoxetine ingestion resulting in neurological and cardiovascular toxicity resulting in death. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulting in\"]], \"start\": [[58]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"massive fluoxetine ingestion\"]], \"start\": [[29]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"fluoxetine\"]], \"start\": [[37]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"massive\"]], \"start\": [[29]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"ingestion\"]], \"start\": [[48]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"neurological and cardiovascular toxicity resulting in death\"]], \"start\": [[71]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"an unusual case\"]], \"start\": [[10]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
9161656_14 | Although dyspnea associated with verapamil administration has been reported, this is the first report of an elderly asymptomatic asthmatic patient with hypertension who developed an acute asthma attack following sustained-release verapamil administration. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[169]], \"entity_id\": [\"T13\"]}, \"Subject\": {\"text\": [[\"an elderly asymptomatic asthmatic patient with hypertension\"]], \"start\": [[105]], \"entity_id\": [\"T12\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[108]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"asymptomatic asthmatic\"]], \"start\": [[116]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"an acute asthma attack\"]], \"start\": [[179]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"sustained-release verapamil administration\"]], \"start\": [[212]], \"entity_id\": [\"T15\"], \"Drug\": {\"text\": [[\"sustained-release verapamil\"]], \"start\": [[212]], \"entity_id\": [\"T16\"]}, \"Disorder\": {\"text\": [[\"hypertension\"]], \"start\": [[152]], \"entity_id\": [\"T17\"]}}}"
}
]
}
] |
11483161_2 | The bleeding resolved on discontinuation of APV. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"resolved\"]], \"start\": [[13]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"discontinuation of APV\"]], \"start\": [[25]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"The bleeding\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"APV\"]], \"start\": [[44]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
16249064_1 | We describe a case of infection with Mycobacterium abscessus in a 67-year-old woman receiving infliximab as a component of her therapy for RA. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[84]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a 67-year-old woman\", \"RA\"]], \"start\": [[64, 139]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"67-year-old\"]], \"start\": [[66]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[78]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"infection with Mycobacterium abscessus\"]], \"start\": [[22]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"infliximab as a component of her therapy\"]], \"start\": [[94]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"infliximab\"]], \"start\": [[94]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"RA\"]], \"start\": [[139]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
2327115_2 | Renal toxicities have been reported in less than one percent of the patients receiving ciprofloxacin therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reported\"]], \"start\": [[27]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Renal toxicities\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"ciprofloxacin therapy.\"]], \"start\": [[87]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"ciprofloxacin\"]], \"start\": [[87]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"less than one percent of the patients\"]], \"start\": [[39]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"less than one percent\"]], \"start\": [[39]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
10513720_1 | Taxane-induced glaucoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[7]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Taxane\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Taxane\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"glaucoma\"]], \"start\": [[15]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
14735388_1 | Ciprofloxacin-induced toxic epidermal necrolysis in a patient with systemic lupus erythematosus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"nduced\"]], \"start\": [[15]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Ciprofloxacin\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Ciprofloxacin\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"systemic lupus erythematosus\"]], \"start\": [[67]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"toxic epidermal necrolysis\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient with systemic lupus erythematosus.\"]], \"start\": [[52]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
15383642_1 | Hypotension due to interaction between lisinopril and tizanidine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due to\"]], \"start\": [[12]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"interaction between lisinopril and tizanidine\"]], \"start\": [[19]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"tizanidine\"], [\"lisinopril\"]], \"start\": [[54], [39]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[19]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"lisinopril\"], [\"tizanidine\"]], \"start\": [[39], [54]], \"entity_id\": [\"T11\", \"T10\"]}}]}, \"Effect\": {\"text\": [[\"Hypotension\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
7538828_8 | Development of an extensive skin rash following a single dose of MTX may be an early warning sign for life-threatening bone marrow aplasia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[38]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"extensive skin rash\"]], \"start\": [[18]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"MTX\"]], \"start\": [[65]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"MTX\"]], \"start\": [[65]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
6159523_1 | Anaphylactoid reaction to 50% solution of dextrose. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[23]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Anaphylactoid reaction\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"50% solution of dextrose\"]], \"start\": [[26]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"dextrose\"]], \"start\": [[42]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
7893301_2 | Hypokalemia after normal doses of neubulized albuterol (salbutamol). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[12]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Hypokalemia\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"normal doses of neubulized albuterol (salbutamol)\"]], \"start\": [[18]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"albuterol\"], [\"salbutamol\"]], \"start\": [[45], [56]], \"entity_id\": [\"T7\", \"T8\"]}, \"Dosage\": {\"text\": [[\"normal doses\"]], \"start\": [[18]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
9770151_1 | Although praziquantel administration may have been effective in killing the parasite in both patients, we are concerned about the production of marked inflammation as a result of treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"production\"]], \"start\": [[130]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"marked inflammation\"]], \"start\": [[144]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"praziquantel\"]], \"start\": [[9]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"praziquantel\"]], \"start\": [[9]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"parasite\"]], \"start\": [[76]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"parasite in both patients\"]], \"start\": [[76]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"both\"]], \"start\": [[88]], \"entity_id\": [\"T9\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[37]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
16503727_3 | We describe a patient who developed granulocytopenia and fever after taking dipyrone and discuss the available literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[26]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[12]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"granulocytopenia and fever\"]], \"start\": [[36]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"taking dipyrone\"]], \"start\": [[69]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"dipyrone\"]], \"start\": [[76]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
20126479_3 | Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"before\"]], \"start\": [[112]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"hydroxychloroquine\"]], \"start\": [[76]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"hydroxychloroquine\"]], \"start\": [[76]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"symptomatic vision loss\"]], \"start\": [[119]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
11961411_1 | A 64-year-old man presented with proteinuria during postoperative interferon (IFN)-beta therapy against malignant melanoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[45]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"proteinuria\"]], \"start\": [[33]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"postoperative interferon (IFN)-beta therapy\"]], \"start\": [[52]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"interferon (IFN)-beta\"]], \"start\": [[66]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"malignant melanoma\"]], \"start\": [[104]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"A 64-year-old man\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"64-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
17509184_2 | Ethambutol toxicity manifesting as acute onset psychosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"toxicity\"]], \"start\": [[11]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Ethambutol\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Ethambutol\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"acute onset psychosis\"]], \"start\": [[35]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
8503421_2 | Cholesterol crystal embolization-associated renal failure after therapy with recombinant tissue-type plasminogen activator. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[58]], \"entity_id\": [\"T1\"]}, \"Treatment\": {\"text\": [[\"therapy with recombinant tissue-type plasminogen activator\"]], \"start\": [[64]], \"entity_id\": [\"T2\"], \"Drug\": {\"text\": [[\"plasminogen activator\"]], \"start\": [[101]], \"entity_id\": [\"T4\"]}}, \"Effect\": {\"text\": [[\"Cholesterol crystal embolization-associated renal failure\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}}"
}
]
}
] |
15289139_2 | METHODS: A 76-year-old woman with primary open-angle glaucoma and no history of ocular surgery developed a choroidal detachment 12 hours after initiation of therapy with dorzolamide eye drops. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[95]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"A 76-year-old woman with primary open-angle glaucoma and no history of ocular surgery\"]], \"start\": [[9]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"76-year-old\"]], \"start\": [[11]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[23]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"choroidal detachment\"]], \"start\": [[107]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"12 hours after initiation of therapy with dorzolamide eye drops\"]], \"start\": [[128]], \"entity_id\": [\"T6\"], \"Time_elapsed\": {\"text\": [[\"12 hours\"]], \"start\": [[128]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"dorzolamide\"]], \"start\": [[170]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"open-angle glaucoma\"]], \"start\": [[42]], \"entity_id\": [\"T12\"]}, \"Route\": {\"text\": [[\"eye drops\"]], \"start\": [[182]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
717931_1 | Life-threatening hyperkalemia induced by arginine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[30]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"hyperkalemia\"]], \"start\": [[17]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"arginine\"]], \"start\": [[41]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"arginine\"]], \"start\": [[41]], \"entity_id\": [\"T6\"]}}, \"Severity\": {\"text\": [[\"Life-threatening\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"value\": \"High\"}}"
}
]
}
] |
11881322_6 | We report on three patients who developed acute liver damage during therapy with itraconazole, and in whom liver biopsy specimens were obtained. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[32]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"three patients\"]], \"start\": [[13]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"three\"]], \"start\": [[13]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"acute liver damage\"]], \"start\": [[42]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"itraconazole\"]], \"start\": [[81]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"itraconazole\"]], \"start\": [[81]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
15126179_2 | METHODS: A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[27]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"A 68-year-old man\"]], \"start\": [[9]], \"entity_id\": [\"T10\"], \"Age\": {\"text\": [[\"68-year-old\"]], \"start\": [[11]], \"entity_id\": [\"T15\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[23]], \"entity_id\": [\"T16\"]}}, \"Effect\": {\"text\": [[\"intense conjunctival hyperemia and cystoid macula edema\"]], \"start\": [[37]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"bimatoprost\"]], \"start\": [[129]], \"entity_id\": [\"T14\"], \"Disorder\": {\"text\": [[\"cataract surgery\"]], \"start\": [[156]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"bimatoprost\"]], \"start\": [[129]], \"entity_id\": [\"T17\"]}}}"
}
]
}
] |
12699871_3 | Tacrolimus (FK506), an immunosuppressant, has been associated with mutism in adults after liver transplant. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated with\"]], \"start\": [[51]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Tacrolimus (FK506), an immunosuppressant\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Tacrolimus\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"mutism\"]], \"start\": [[67]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"adults after liver transplant\"]], \"start\": [[77]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"adults\"]], \"start\": [[77]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"liver transplant.\"]], \"start\": [[90]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
19904536_13 | Gemcitabine-induced pulmonary toxicity is usually a dramatic condition. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[12]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Gemcitabine\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Gemcitabine\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"pulmonary toxicity\"]], \"start\": [[20]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"dramatic\"]], \"start\": [[52]], \"entity_id\": [\"T7\"], \"value\": \"High\"}}"
}
]
}
] |
6987607_1 | However, the amount of prednisone required to maintain normotension resulted in Cushingoid features and has been discontinued. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulted in\"]], \"start\": [[68]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Cushingoid features\"]], \"start\": [[80]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"prednisone\", \"to maintain normotension\"]], \"start\": [[23, 43]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"prednisone\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
8140860_2 | We present the case of a woman undergoing treatment with acenocoumarol for deep vein thrombosis, who maintained an international normalized ratio (INR) of between 2.5 and 4 for 2 months. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[42]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a woman\"]], \"start\": [[23]], \"entity_id\": [\"T5\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[25]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"acenocoumarol\"]], \"start\": [[57]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"acenocoumarol\"]], \"start\": [[57]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"deep vein thrombosis\"]], \"start\": [[75]], \"entity_id\": [\"T1\"]}}}"
}
]
}
] |
18408649_1 | Development of tics in a thirteen-year-old male following atomoxetine use. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[48]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"atomoxetine\"]], \"start\": [[58]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"atomoxetine\"]], \"start\": [[58]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"Development of tics\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a thirteen-year-old male\"]], \"start\": [[23]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"thirteen-year-old\"]], \"start\": [[25]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[43]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
7919557_3 | OBJECTIVE: To report a case of chronic, nonproductive cough secondary to the angiotensin-converting enzyme (ACE) inhibitor quinapril, with complete resolution after switching to another ACE inhibitor, fosinopril. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"resolution\"]], \"start\": [[148]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"chronic, nonproductive cough secondary to the angiotensin-converting enzyme (ACE) inhibitor quinapril\"]], \"start\": [[31]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"switching to another ACE inhibitor, fosinopril\"]], \"start\": [[165]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"fosinopril\"]], \"start\": [[201]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
17163271_1 | Cholelithiasis and thrombosis of the central retinal vein in a renal transplant recipient treated with cyclosporin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[58]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a renal transplant recipient\"]], \"start\": [[61]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"renal transplant\"]], \"start\": [[63]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"cyclosporin\"]], \"start\": [[103]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"cyclosporin\"]], \"start\": [[103]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"Cholelithiasis and thrombosis of the central retinal vein\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
11788010_6 | We report a case of hepatolithiasis (intrahepatic stone) complicated by gram-negative sepsis in a 37 year old male with acromegaly being treated with octreotide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[93]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"hepatolithiasis (intrahepatic stone) complicated by gram-negative sepsis\"]], \"start\": [[20]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a 37 year old male with acromegaly\"]], \"start\": [[96]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"37 year old\"]], \"start\": [[98]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[110]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"octreotide\"]], \"start\": [[150]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"octreotide\"]], \"start\": [[150]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"acromegaly\"]], \"start\": [[120]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
1288290_1 | Proliferation of abnormal bone marrow histiocytes, an undesired effect of granulocyte macrophage-colony-stimulating factor therapy in a patient with Hurler's syndrome undergoing bone marrow transplantation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"undesired effect\"]], \"start\": [[54]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Proliferation of abnormal bone marrow histiocytes\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"granulocyte macrophage-colony-stimulating factor\"]], \"start\": [[74]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"granulocyte macrophage-colony-stimulating factor\"]], \"start\": [[74]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"Hurler's syndrome\"]], \"start\": [[149]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"a patient with Hurler's syndrome\"]], \"start\": [[134]], \"entity_id\": [\"T3\"]}}"
}
]
}
] |
18431096_2 | We report 4 patients, 2 on methylphenidate and 2 on dextroamphetamine who presented with acral cyanosis, livedo reticularis, or Raynaud phenomenon. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[74]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"dextroamphetamine\"]], \"start\": [[52]], \"entity_id\": [\"T18\"], \"Drug\": {\"text\": [[\"dextroamphetamine\"]], \"start\": [[52]], \"entity_id\": [\"T14\"]}}, \"Subject\": {\"text\": [[\"2\"]], \"start\": [[47]], \"entity_id\": [\"T17\"]}, \"Effect\": {\"text\": [[\"acral cyanosis, livedo reticularis, or Raynaud phenomenon\"]], \"start\": [[89]], \"entity_id\": [\"T10\"]}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[74]], \"entity_id\": [\"T12\"]}, \"Effect\": {\"text\": [[\"acral cyanosis, livedo reticularis, or Raynaud phenomenon\"]], \"start\": [[89]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"methylphenidate\"]], \"start\": [[27]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"methylphenidate\"]], \"start\": [[27]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"4 patients, 2 on\"]], \"start\": [[10]], \"entity_id\": [\"T15\"]}}"
}
]
}
] |
10575189_1 | Described here are 2 patients who developed thrombotic microangiopathy of the kidneys after receiving high cumulative doses of the new anticancer drug gemcitabine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[92]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"thrombotic microangiopathy of the kidneys\"]], \"start\": [[44]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"gemcitabine\"]], \"start\": [[151]], \"entity_id\": [\"T5\"], \"Dosage\": {\"text\": [[\"high cumulative doses\"]], \"start\": [[102]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"gemcitabine\"]], \"start\": [[151]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"2 patients\"]], \"start\": [[19]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"2\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
15840734_11 | CONCLUSIONS: An objective causality assessment revealed that fluphenazine was the probable cause of NMS in this patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[91]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"fluphenazine\"]], \"start\": [[61]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"fluphenazine\"]], \"start\": [[61]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"NMS\"]], \"start\": [[100]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[112]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
9754850_2 | Like other atypical neuroleptics olanzapine is considered to show a reduced prevalence of extrapyramidal side effects when compared to classical neuroleptic drugs. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"show\"]], \"start\": [[61]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"reduced prevalence of extrapyramidal side effects\"]], \"start\": [[68]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"olanzapine\"]], \"start\": [[33]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"olanzapine\"], [\"neuroleptic drugs.\"]], \"start\": [[33], [145]], \"entity_id\": [\"T7\", \"T8\"]}}}"
}
]
}
] |
8192712_1 | Based on our experience and on previously published data, serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"present\"]], \"start\": [[150]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"valproic acid therapy\"]], \"start\": [[124]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"ED\"]], \"start\": [[109]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"valproic acid\"]], \"start\": [[124]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"all ED patients\"]], \"start\": [[105]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"altered mental status\"]], \"start\": [[163]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"appear to be\"]], \"start\": [[79]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
12581772_3 | Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[118]], \"entity_id\": [\"T22\"]}, \"Treatment\": {\"text\": [[\"Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia)\"]], \"start\": [[0]], \"entity_id\": [\"T21\"], \"Drug\": {\"text\": [[\"Rapamycin/sirolimus\"]], \"start\": [[0]], \"entity_id\": [\"T29\"]}}, \"Effect\": {\"text\": [[\"myelosuppression, hypertension, hyperlipidemia, and infection\"]], \"start\": [[134]], \"entity_id\": [\"T1\"]}}"
}
]
}
] |
12889716_1 | Enoxaparin-induced generalized exanthem. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"generalized exanthem\"]], \"start\": [[19]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Enoxaparin\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Enoxaparin\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
7776854_1 | Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far, and comprise the first cases of (sub)fulminant hepatitis and cirrhosis related to benzarone. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[43]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"benzarone\"]], \"start\": [[46]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"benzarone\"], [\"benzarone\"]], \"start\": [[46], [170]], \"entity_id\": [\"T12\", \"T13\"]}}, \"Effect\": {\"text\": [[\"hepatotoxicity\", \"(sub)fulminant hepatitis and cirrhosis\"]], \"start\": [[56, 120]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
24163322_8 | Within 3 days after starting bismuth subsalicylate therapy, the patient's INR increased from 2.56 to 3.54 and minor bleeding was noted from the patient's tracheostomy site. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"noted\"]], \"start\": [[129]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Within 3 days after starting bismuth subsalicylate therapy\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Duration\": {\"text\": [[\"3 days\"]], \"start\": [[7]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"bismuth subsalicylate\"]], \"start\": [[29]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"the patient\"]], \"start\": [[60]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"INR increased from 2.56 to 3.54 and minor bleeding was noted from the patient's tracheostomy site\"]], \"start\": [[74]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"minor\"]], \"start\": [[110]], \"entity_id\": [\"T8\"], \"value\": \"Low\"}}"
}
]
}
] |
19667003_4 | After three weeks of carbamazepine therapy, the patient arrived at the emergency department (ED) with severe agitation and aggressive behavior. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"After\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[48]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"severe agitation and aggressive behavior\"]], \"start\": [[102]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"After three weeks of carbamazepine therapy\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Duration\": {\"text\": [[\"three weeks\"]], \"start\": [[6]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"carbamazepine\"]], \"start\": [[21]], \"entity_id\": [\"T11\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[102]], \"entity_id\": [\"T9\"], \"value\": \"Medium\"}}"
}
]
}
] |
1504404_4 | OBJECTIVE: To report a case of ciprofloxacin-induced psychosis and to discuss occurrence rates, risk factors, possible etiologies, preventive measures, and treatment courses for this adverse reaction. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[45]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"ciprofloxacin\"]], \"start\": [[31]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"ciprofloxacin\"]], \"start\": [[31]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"psychosis\"]], \"start\": [[53]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
12126225_3 | A 77-year-old man developed ankle, hand, and facial swelling 2 weeks after starting rosiglitazone. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[18]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"A 77-year-old man\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"77-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"ankle, hand, and facial swelling\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"2 weeks after starting rosiglitazone\"]], \"start\": [[61]], \"entity_id\": [\"T6\"], \"Time_elapsed\": {\"text\": [[\"2 weeks\"]], \"start\": [[61]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"rosiglitazone\"]], \"start\": [[84]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
3659584_5 | Although rare, massive pulmonary embolus must be considered to be a major risk of thrombolytic therapy for deep venous thrombosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"risk\"]], \"start\": [[74]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"massive pulmonary embolus\"]], \"start\": [[15]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"thrombolytic\"]], \"start\": [[82]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"thrombolytic\"]], \"start\": [[82]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
7781845_5 | We report a case of hypoglycaemia after mefloquine therapy (1,500 mg over two days) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[34]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"hypoglycaemia\"]], \"start\": [[20]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"mefloquine therapy (1,500 mg over two days)\"]], \"start\": [[40]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"severe gastrointestinal cryptosporidiasis\"]], \"start\": [[88]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"mefloquine\"]], \"start\": [[40]], \"entity_id\": [\"T17\"]}, \"Dosage\": {\"text\": [[\"1,500 mg\"]], \"start\": [[60]], \"entity_id\": [\"T18\"]}}, \"Subject\": {\"text\": [[\"a cachectic AIDS patient with protracted diarrhoea\"]], \"start\": [[133]], \"entity_id\": [\"T13\"], \"Disorder\": {\"text\": [[\"cachectic AIDS\"], [\"protracted diarrhoea\"]], \"start\": [[135], [163]], \"entity_id\": [\"T15\", \"T16\"]}}}"
}
]
}
] |
9876812_3 | OBJECTIVE: To describe onset of syndrome of inappropriate antidiuretic hormone (SIADH) associated with vinorelbine therapy for advanced breast cancer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated with\"]], \"start\": [[87]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"syndrome of inappropriate antidiuretic hormone (SIADH)\"]], \"start\": [[32]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"vinorelbine\"]], \"start\": [[103]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"vinorelbine\"]], \"start\": [[103]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"advanced breast cancer\"]], \"start\": [[127]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
11160777_9 | The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are "insulin sensitizers" and exert direct effects on the mechanisms of insulin resistance. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"exert\"]], \"start\": [[128]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"thiazolidinediones\"]], \"start\": [[4]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"insulin resistance\"]], \"start\": [[170]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
15611427_4 | The exacerbation of psoriasis was accompanied by a massive induction of lesional type I interferon activity, detected by MxA expression after imiquimod therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"detected\"]], \"start\": [[109]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"imiquimod\"]], \"start\": [[142]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"imiquimod\"]], \"start\": [[142]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"exacerbation of psoriasis\", \"a massive induction of lesional type I interferon activity\"]], \"start\": [[4, 49]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
2857534_3 | Two patients treated with alprazolam had histories suggestive of a bipolar disorder and developed lithium-responsive manic episodes. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[88]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"Two patients\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"Two\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"a bipolar disorder\"]], \"start\": [[65]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"alprazolam\"]], \"start\": [[26]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"alprazolam\"]], \"start\": [[26]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"lithium-responsive manic episodes\"]], \"start\": [[98]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
8292513_1 | Cerebrovascular complications of L-asparaginase therapy in children with leukemia: aphasia and other neuropsychological deficits. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complications\"]], \"start\": [[16]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"Cerebrovascular complications\", \"aphasia and other neuropsychological deficits\"]], \"start\": [[0, 83]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"L-asparaginase\"]], \"start\": [[33]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"L-asparaginase\"]], \"start\": [[33]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"leukemia\"]], \"start\": [[73]], \"entity_id\": [\"T14\"]}}, \"Subject\": {\"text\": [[\"children with leukemia\"]], \"start\": [[59]], \"entity_id\": [\"T9\"], \"Age\": {\"text\": [[\"children\"]], \"start\": [[59]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
15752306_2 | We report two patients who developed intense livedo reticularis clearly related to the administration of interferon alpha 2b as an adjuvant therapy for melanoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[72]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"two patients\"]], \"start\": [[10]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[10]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"interferon alpha 2b as an adjuvant therapy for melanoma\"]], \"start\": [[105]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"interferon alpha 2b\"]], \"start\": [[105]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"melanoma\"]], \"start\": [[152]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"intense livedo reticularis\"]], \"start\": [[37]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
6833205_1 | A case of SIADH associated with desipramine treatment in an elderly depressed woman is described. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[16]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"SIADH\"]], \"start\": [[10]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"desipramine treatment\"]], \"start\": [[32]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"depressed\"]], \"start\": [[68]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"desipramine\"]], \"start\": [[32]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"an elderly depressed woman\"]], \"start\": [[57]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[60]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[78]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
7379406_1 | Niflumic acid-induced skeletal fluorosis: iatrogenic disease or therapeutic perspective for osteoporosis? | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[14]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Niflumic acid\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"Niflumic acid\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"skeletal fluorosis\"]], \"start\": [[22]], \"entity_id\": [\"T8\"]}, \"Speculated\": {\"text\": [[\"?\"]], \"start\": [[104]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
6149250_5 | Both patients developed severe complications when treated with aminoglutethimide as a cancer hormonal therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[14]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"aminoglutethimide\"]], \"start\": [[63]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"cancer\"]], \"start\": [[86]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"aminoglutethimide\"]], \"start\": [[63]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"Both patients\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"severe complications\"]], \"start\": [[24]], \"entity_id\": [\"T11\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[24]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
10458196_2 | An 11-day-old infant became lethargic and apneic after a single drop of brimonidine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"became\"]], \"start\": [[21]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"An 11-day-old infant\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"11-day-old\"], [\"infant\"]], \"start\": [[3], [14]], \"entity_id\": [\"T11\", \"T12\"]}}, \"Effect\": {\"text\": [[\"lethargic and apneic\"]], \"start\": [[28]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"a single drop of brimonidine\"]], \"start\": [[55]], \"entity_id\": [\"T7\"], \"Dosage\": {\"text\": [[\"single drop\"]], \"start\": [[57]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"brimonidine\"]], \"start\": [[72]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
6159523_3 | Investigations suggested that the dextrose, rather than any additives, was responsible for the reaction. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"responsible\"]], \"start\": [[75]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"dextrose\"]], \"start\": [[34]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"dextrose\"]], \"start\": [[34]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"the reaction\"]], \"start\": [[91]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
10660641_8 | Since renal insufficiency was induced by AMPH and the other antifungal drugs were ineffective, daily administration of 200 mg of ITCZ was initiated, and the inflammatory signs and symptoms gradually subsided. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"initiated\"]], \"start\": [[138]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"daily administration of 200 mg of ITCZ\"]], \"start\": [[95]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"renal insufficiency\"]], \"start\": [[6]], \"entity_id\": [\"T15\"]}, \"Dosage\": {\"text\": [[\"200 mg\"]], \"start\": [[119]], \"entity_id\": [\"T12\"]}, \"Freq\": {\"text\": [[\"daily administration\"]], \"start\": [[95]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"ITCZ\"]], \"start\": [[129]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"the inflammatory signs and symptoms gradually subsided.\"]], \"start\": [[153]], \"entity_id\": [\"T11\"]}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[30]], \"entity_id\": [\"T17\"]}, \"Effect\": {\"text\": [[\"renal insufficiency\"]], \"start\": [[6]], \"entity_id\": [\"T19\"]}, \"Treatment\": {\"text\": [[\"AMPH\"]], \"start\": [[41]], \"entity_id\": [\"T20\"], \"Drug\": {\"text\": [[\"AMPH\"]], \"start\": [[41]], \"entity_id\": [\"T18\"]}}}"
}
]
}
] |
7696938_2 | Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[70]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"cardiac arrhythmia\"]], \"start\": [[51]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"amphotericin B administration\"]], \"start\": [[77]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"amphotericin B\"]], \"start\": [[77]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
1356045_1 | Acute myopathy with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and vecuronium. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[63]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Acute myopathy with selective degeneration of myosin filaments\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"methylprednisolone\", \"vecuronium\"]], \"start\": [[105, 128]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"asthmaticus\"]], \"start\": [[80]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"methylprednisolone\"], [\"vecuronium\"]], \"start\": [[105], [128]], \"entity_id\": [\"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[124]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"vecuronium\"], [\"methylprednisolone\"]], \"start\": [[128], [105]], \"entity_id\": [\"T12\", \"T11\"]}}]}}"
}
]
}
] |
1124417_1 | Presented is a case of acute renal failure induced by acetazolamide therapy for glaucoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[43]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"acute renal failure\"]], \"start\": [[23]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"acetazolamide therapy for glaucoma\"]], \"start\": [[54]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"acetazolamide\"]], \"start\": [[54]], \"entity_id\": [\"T6\"]}, \"Disorder\": {\"text\": [[\"glaucoma\"]], \"start\": [[80]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
10803790_6 | Cyanamide-induced liver dysfunction after abstinence in alcoholics: a long-term follow-up study on four cases. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[10]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Cyanamide\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Cyanamide\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"liver dysfunction\"]], \"start\": [[18]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"abstinence in alcoholics\"]], \"start\": [[42]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
16680561_10 | Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reported\"]], \"start\": [[206]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"desipramine or cinacalcet\"]], \"start\": [[248]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"desipramine\"], [\"cinacalcet\"], [\"desipramine\"], [\"desipramine\"], [\"cinacalcet\"]], \"start\": [[248], [263], [64], [102], [119]], \"entity_id\": [\"T15\", \"T16\", \"T17\", \"T18\", \"T19\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[114]], \"entity_id\": [\"T20\"]}, \"Drug\": {\"text\": [[\"desipramine\"], [\"cinacalcet\"]], \"start\": [[102], [119]], \"entity_id\": [\"T18\", \"T19\"]}}]}, \"Effect\": {\"text\": [[\"nausea and headache\"]], \"start\": [[175]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[219]], \"entity_id\": [\"T22\"]}}"
}
]
}
] |
412488_2 | Three patients developed proteinuria following gold therapy for rheumatoid arthritis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[37]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"Three patients\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"Three\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}}, \"Treatment\": {\"text\": [[\"gold\"]], \"start\": [[47]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"]], \"start\": [[64]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"gold\"]], \"start\": [[47]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"proteinuria\"]], \"start\": [[25]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
9892272_3 | The authors report a case of a patient who received alteplase for acute myocardial infarction and developed spontaneous subfascial hematoma without any evidence of direct trauma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[98]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a case of a patient\"]], \"start\": [[19]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"alteplase\"]], \"start\": [[52]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"acute myocardial infarction\"]], \"start\": [[66]], \"entity_id\": [\"T4\"]}, \"Drug\": {\"text\": [[\"alteplase\"]], \"start\": [[52]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"spontaneous subfascial hematoma without any evidence of direct trauma\"]], \"start\": [[108]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
12121061_1 | Ticlopidine-induced marrow aplasia treated with cyclosporine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[12]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Ticlopidine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"Ticlopidine\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"marrow aplasia\"]], \"start\": [[20]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
6947095_1 | Dural sinus thrombosis developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate, prednisone, and asparaginase. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[23]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Dural sinus thrombosis\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"two children with acute lymphoblastic leukemia\"]], \"start\": [[36]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[36]], \"entity_id\": [\"T9\"]}, \"Age\": {\"text\": [[\"children\"]], \"start\": [[40]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"induction treatment with vincristine sulfate, prednisone, and asparaginase\"]], \"start\": [[90]], \"entity_id\": [\"T14\"], \"Drug\": {\"text\": [[\"vincristine sulfate\"], [\"prednisone\"], [\"asparaginase\"]], \"start\": [[115], [136], [152]], \"entity_id\": [\"T11\", \"T12\", \"T13\"]}, \"Disorder\": {\"text\": [[\"acute lymphoblastic leukemia\"]], \"start\": [[54]], \"entity_id\": [\"T15\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[148]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"vincristine sulfate\"], [\"prednisone\"], [\"asparaginase\"]], \"start\": [[115], [136], [152]], \"entity_id\": [\"T11\", \"T12\", \"T13\"]}}]}}"
}
]
}
] |
8926752_1 | Zolpidem (Ambien), a relatively new nonbenzodiazepine sedative-hypnotic, was involved in the death of a 39-year-old obese male who was being treated for depression and insomnia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"involved\"]], \"start\": [[77]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"death\"]], \"start\": [[93]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a 39-year-old obese male\"]], \"start\": [[102]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"39-year-old\"]], \"start\": [[104]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"obese\"]], \"start\": [[116]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[122]], \"entity_id\": [\"T11\"]}}, \"Treatment\": {\"text\": [[\"Zolpidem (Ambien)\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"depression and insomnia\"]], \"start\": [[153]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"Zolpidem\"]], \"start\": [[0]], \"entity_id\": [\"T13\"]}}, \"Severity\": {\"text\": [[\"death\"]], \"start\": [[93]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
9494448_1 | A MEDLINE search identified all the reported cases of hypersensitivity reactions to cyclosporine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reactions\"]], \"start\": [[71]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"hypersensitivity reactions\"]], \"start\": [[54]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"cyclosporine\"]], \"start\": [[84]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"cyclosporine\"]], \"start\": [[84]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
16029707_2 | METHODS: A 79-year-old woman being treated with imiquimod 5 days per week for a nodular basal cell developed a verrucous plaque over the treatment area after 7 weeks of therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[99]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"A 79-year-old woman\"]], \"start\": [[9]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"79-year-old\"]], \"start\": [[11]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[23]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"imiquimod 5 days per week\", \"after 7 weeks\"]], \"start\": [[48, 152]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"nodular basal cell\"]], \"start\": [[80]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"imiquimod\"]], \"start\": [[48]], \"entity_id\": [\"T10\"]}, \"Freq\": {\"text\": [[\"5 days per week\"]], \"start\": [[58]], \"entity_id\": [\"T11\"]}, \"Time_elapsed\": {\"text\": [[\"7 weeks\"]], \"start\": [[158]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"verrucous plaque\"]], \"start\": [[111]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
22735246_2 | Oxcarbazepine, a metabolite of carbamazepine, is used as an antiepileptic, analgesic for neuropathic pain and in the treatment of affective disorders. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"used\"]], \"start\": [[49]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Oxcarbazepine\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"neuropathic pain\"], [\"affective disorder\"]], \"start\": [[89], [130]], \"entity_id\": [\"T11\", \"T12\"]}, \"Drug\": {\"text\": [[\"Oxcarbazepine\"]], \"start\": [[0]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"antiepileptic, analgesic\"]], \"start\": [[60]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
15543388_3 | PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and ribavirin for 6 months, developed progressive malaise and anemia 6 months after the end of treatment. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[146]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"A 34-year-old woman with chronic hepatitis C, genotype 3\"]], \"start\": [[20]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"34-year-old\"]], \"start\": [[22]], \"entity_id\": [\"T11\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[34]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"genotype 3\"]], \"start\": [[66]], \"entity_id\": [\"T13\"]}}, \"Treatment\": {\"text\": [[\"pegylated interferon alpha-2a and ribavirin for 6 months\"]], \"start\": [[88]], \"entity_id\": [\"T9\"], \"Duration\": {\"text\": [[\"6 months\"]], \"start\": [[136]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"pegylated interferon alpha-2a\"], [\"ribavirin\"]], \"start\": [[88], [122]], \"entity_id\": [\"T16\", \"T17\"]}, \"Time_elapsed\": {\"text\": [[\"6 months\"]], \"start\": [[187]], \"entity_id\": [\"T1\"]}, \"Disorder\": {\"text\": [[\"chronic hepatitis C\"]], \"start\": [[45]], \"entity_id\": [\"T2\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[118]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"ribavirin\"], [\"pegylated interferon alpha-2a\"]], \"start\": [[122], [88]], \"entity_id\": [\"T17\", \"T16\"]}}]}, \"Effect\": {\"text\": [[\"progressive malaise and anemia\"]], \"start\": [[156]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
19224802_5 | We report on three cases wherein treatment of dexmedetomidine-induced bradycardia with i.v. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[62]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"treatment of dexmedetomidine\"]], \"start\": [[33]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"dexmedetomidine\"]], \"start\": [[46]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"bradycardia with i.v\"]], \"start\": [[70]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
1688693_4 | Esmolol, an ultrashort-acting beta 1-selective antagonist, controlled her multiple dysrhythmias and symptoms of sympathetic nervous system hyperstimulation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"controlled\"]], \"start\": [[59]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Esmolol, an ultrashort-acting beta 1-selective antagonist\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"multiple dysrhythmias and symptoms of sympathetic nervous system hyperstimulation\"]], \"start\": [[74]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"Esmolol\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"her\"]], \"start\": [[70]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
25671244_4 | (Case 1) A 29-year-old woman with overdose of metaxalone presented to the emergency department with altered mental status, seizure-like activity, hyperthermia, rigidity in the lower extremities, myoclonus, and hyperreflexia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[57]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"A 29-year-old woman\"]], \"start\": [[9]], \"entity_id\": [\"T10\"], \"Age\": {\"text\": [[\"29-year-old\"]], \"start\": [[11]], \"entity_id\": [\"T14\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[23]], \"entity_id\": [\"T15\"]}}, \"Treatment\": {\"text\": [[\"metaxalone\"]], \"start\": [[46]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"metaxalone\"]], \"start\": [[46]], \"entity_id\": [\"T16\"]}, \"Dosage\": {\"text\": [[\"overdose\"]], \"start\": [[34]], \"entity_id\": [\"T17\"]}}, \"Effect\": {\"text\": [[\"altered mental status, seizure-like activity, hyperthermia, rigidity in the lower extremities, myoclonus, and hyperreflexia\"]], \"start\": [[100]], \"entity_id\": [\"T13\"]}}"
}
]
}
] |
25515435_1 | Warfarin and boceprevir interaction causing subtherapeutic international normalized ratio: a case report. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"causing\"]], \"start\": [[36]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Warfarin\", \"boceprevir\"]], \"start\": [[0, 13]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"Warfarin\"], [\"boceprevir\"]], \"start\": [[0], [13]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[24]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"Warfarin\"], [\"boceprevir\"]], \"start\": [[0], [13]], \"entity_id\": [\"T9\", \"T10\"]}}]}, \"Effect\": {\"text\": [[\"subtherapeutic international normalized ratio\"]], \"start\": [[44]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
3569037_1 | A brief review of reported cases of chloramphenicol hypersensitivity in the English-language literature, as well as possible alternative explanations in this case, are provided. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[33]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"chloramphenicol\"]], \"start\": [[36]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"chloramphenicol\"]], \"start\": [[36]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hypersensitivity\"]], \"start\": [[52]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
6692713_2 | Possible recurrence of amiodarone pulmonary toxicity following corticosteroid therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[53]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"amiodarone pulmonary toxicity\"]], \"start\": [[23]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"corticosteroid\"]], \"start\": [[63]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"amiodarone\"], [\"corticosteroid\"]], \"start\": [[23], [63]], \"entity_id\": [\"T6\", \"T7\"]}}, \"Speculated\": {\"text\": [[\"Possible\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
10466445_3 | In the present study, arsenic trioxide was given intravenously for 42 days to a 56-year-old female patient suffering from chemotherapy/ATRA-resistant APL, with 43% APL blasts in the bone marrow and elevated D-dimers. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"given\"]], \"start\": [[43]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"56-year-old female patient\"]], \"start\": [[80]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"56-year-old\"]], \"start\": [[80]], \"entity_id\": [\"T11\"]}, \"Gender\": {\"text\": [[\"female\"]], \"start\": [[92]], \"entity_id\": [\"T12\"]}}, \"Treatment\": {\"text\": [[\"arsenic trioxide\"]], \"start\": [[22]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"arsenic trioxide\"]], \"start\": [[22]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"chemotherapy/ATRA-resistant APL\"]], \"start\": [[122]], \"entity_id\": [\"T15\"]}, \"Duration\": {\"text\": [[\"42 days\"]], \"start\": [[67]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
1765991_4 | We assume that rIFN-gamma induced the de novo development of SLE in our patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[26]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"rIFN-gamma\"]], \"start\": [[15]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"rIFN-gamma\"]], \"start\": [[15]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"the de novo development of SLE\"]], \"start\": [[34]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"our patient\"]], \"start\": [[68]], \"entity_id\": [\"T8\"]}, \"Speculated\": {\"text\": [[\"assume\"]], \"start\": [[3]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
6519218_2 | Interstitial pneumopathy and low-dosage amiodarone. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[25]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"low-dosage amiodarone\"]], \"start\": [[29]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[40]], \"entity_id\": [\"T6\"]}, \"Dosage\": {\"text\": [[\"low-dosage\"]], \"start\": [[29]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Interstitial pneumopathy\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
19995222_2 | CONCLUSIONS: These results suggest that clozapine may cause TD; however, the prevalence is low and the severity is relatively mild, with no or mild self-reported discomfort. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[54]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"TD\"]], \"start\": [[60]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"clozapine\"]], \"start\": [[40]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"clozapine\"]], \"start\": [[40]], \"entity_id\": [\"T10\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[50]], \"entity_id\": [\"T6\"], \"value\": true}, \"Severity\": {\"text\": [[\"mild\"]], \"start\": [[126]], \"entity_id\": [\"T9\"], \"value\": \"Low\"}}"
}
]
}
] |
17228132_8 | Hepatotoxicity resolved once erlotinib was discontinued and serum transaminases returned to baseline normal values. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"discontinued\"]], \"start\": [[43]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Hepatotoxicity\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"erlotinib\"]], \"start\": [[29]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"Hepatotoxicity\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"erlotinib\"]], \"start\": [[29]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
9161656_15 | CONCLUSIONS: Sustained-release verapamil is thought to be the cause of the asthma attack in this patient because she was not taking any other preparations; the symptoms started with the administration of sustained-release verapamil and were relieved after its discontinuation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[62]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Sustained-release verapamil\"]], \"start\": [[13]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"verapamil\"]], \"start\": [[31]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"asthma attack\"]], \"start\": [[75]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
150825_1 | A patient developed cholestatic hepatitis while being treated with nitrofurantoin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[10]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"cholestatic hepatitis\"]], \"start\": [[20]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"nitrofurantoin\"]], \"start\": [[67]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"nitrofurantoin\"]], \"start\": [[67]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
19826099_2 | Severe apnea in an infant exposed to lamotrigine in breast milk. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[13]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"apnea\"]], \"start\": [[7]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"lamotrigine\"]], \"start\": [[37]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"lamotrigine\"]], \"start\": [[37]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"breast milk\"]], \"start\": [[52]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"an infant\"]], \"start\": [[16]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"infant\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[0]], \"entity_id\": [\"T10\"], \"value\": \"High\"}}"
}
]
}
] |
2894766_3 | Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[119]], \"entity_id\": [\"T13\"]}, \"Subject\": {\"text\": [[\"a 43-year-old man\"]], \"start\": [[132]], \"entity_id\": [\"T9\"], \"Age\": {\"text\": [[\"43-year-old\"]], \"start\": [[134]], \"entity_id\": [\"T14\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[146]], \"entity_id\": [\"T15\"]}}, \"Treatment\": {\"text\": [[\"long-term sulfasalazine\"]], \"start\": [[169]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"chronic ulcerative colitis\"]], \"start\": [[205]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"sulfasalazine\"]], \"start\": [[179]], \"entity_id\": [\"T16\"]}}, \"Effect\": {\"text\": [[\"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}}"
}
]
}
] |
3166573_1 | Bone formation induced in an infant by systemic prostaglandin-E2 administration. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[15]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Bone formation\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"an infant\"]], \"start\": [[26]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"infant\"]], \"start\": [[29]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"systemic prostaglandin-E2 administration\"]], \"start\": [[39]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"prostaglandin-E2\"]], \"start\": [[48]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"systemic\", \"administration\"]], \"start\": [[39, 65]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
8244201_1 | A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; one patient became unconscious. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[29]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"A high dose of cotrimoxazole\", \"after several days of the drug administration\"]], \"start\": [[0, 151]], \"entity_id\": [\"T10\"], \"Dosage\": {\"text\": [[\"high dose\"]], \"start\": [[2]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"cotrimoxazole\"]], \"start\": [[15]], \"entity_id\": [\"T15\"]}, \"Time_elapsed\": {\"text\": [[\"several days\"]], \"start\": [[157]], \"entity_id\": [\"T16\"]}}, \"Effect\": {\"text\": [[\"hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N-acetyl glucosaminase\"]], \"start\": [[37]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"these patients\"]], \"start\": [[200]], \"entity_id\": [\"T17\"]}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"became\"]], \"start\": [[228]], \"entity_id\": [\"T19\"]}, \"Treatment\": {\"text\": [[\"A high dose of cotrimoxazole\", \"after several days of the drug administration\"]], \"start\": [[0, 151]], \"entity_id\": [\"T10\"], \"Dosage\": {\"text\": [[\"high dose\"]], \"start\": [[2]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"cotrimoxazole\"]], \"start\": [[15]], \"entity_id\": [\"T15\"]}, \"Time_elapsed\": {\"text\": [[\"several days\"]], \"start\": [[157]], \"entity_id\": [\"T16\"]}}, \"Subject\": {\"text\": [[\"one patient\"]], \"start\": [[216]], \"entity_id\": [\"T12\"], \"Population\": {\"text\": [[\"one\"]], \"start\": [[216]], \"entity_id\": [\"T18\"]}}, \"Effect\": {\"text\": [[\"unconscious\"]], \"start\": [[235]], \"entity_id\": [\"T20\"]}}"
}
]
}
] |
16641839_2 | Angioedema, a rare side effect of carbamazepine, involves vascular leakage in dermis and subcutis mediated by immunoglobulin E and/or bradykinins. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[31]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Angioedema\", \"involves vascular leakage in dermis and subcutis mediated by immunoglobulin E and/or bradykinins\"]], \"start\": [[0, 49]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"carbamazepine\"]], \"start\": [[34]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"carbamazepine\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
18343993_1 | A diagnosis of trastuzumab-induced pneumonitis was made. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[27]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"trastuzumab\"]], \"start\": [[15]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"trastuzumab\"]], \"start\": [[15]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"pneumonitis\"]], \"start\": [[35]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
10885900_3 | We present a case of HUS in an advanced ovarian cancer patient treated with carboplatin and gemcitabine, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up. | true | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[63]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"HUS\"]], \"start\": [[21]], \"entity_id\": [\"T16\"]}, \"Treatment\": {\"text\": [[\"carboplatin and gemcitabine\"]], \"start\": [[76]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"advanced ovarian cancer\"]], \"start\": [[31]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"carboplatin\"], [\"gemcitabine\"]], \"start\": [[76], [92]], \"entity_id\": [\"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E3\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[88]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"carboplatin\"], [\"gemcitabine\"]], \"start\": [[76], [92]], \"entity_id\": [\"T11\", \"T12\"]}}]}}"
},
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[141]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"favorable outcome\"]], \"start\": [[123]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"chemotherapy interruption and supportive care with a 1 year follow-up\"]], \"start\": [[147]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"HUS\"]], \"start\": [[21]], \"entity_id\": [\"T17\"]}}, \"Subject\": {\"text\": [[\"an advanced ovarian cancer patient\"]], \"start\": [[28]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
17034541_2 | Several such HBV reactivations were reported after combined rituximab and multiagent chemotherapy for B-cell lymphomas. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[45]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Several such HBV reactivations\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"combined rituximab and multiagent chemotherapy\"]], \"start\": [[51]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"rituximab\"]], \"start\": [[60]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"B-cell lymphomas\"]], \"start\": [[102]], \"entity_id\": [\"T10\"]}, \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[85]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.